Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.

Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Coquard IR, Meeus P, Fayette J, Flechon A, Le Cesne A, Penel N, Tredan O, Blay JY.

Oncotarget. 2015 Jul 21. [Epub ahead of print]

2.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S.

Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28.

PMID:
26028518
3.

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.

Houédé N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Fléchon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D.

BMC Cancer. 2015 Apr 4;15:222. doi: 10.1186/s12885-015-1257-2.

4.

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.

Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K.

Lancet Oncol. 2015 Apr;16(4):417-25. doi: 10.1016/S1470-2045(15)70025-2. Epub 2015 Mar 3.

PMID:
25743937
5.

Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.

Houédé N, Dupuy L, Fléchon A, Beuzeboc P, Gravis G, Laguerre B, Théodore C, Culine S, Filleron T, Chevreau C.

BJU Int. 2015 Jan 20. doi: 10.1111/bju.13054. [Epub ahead of print]

PMID:
25601543
6.

[Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer].

Meyer V, Flechon A, Tartas S, Fassi-Fehri H, Ruffion A, Martin X, Colombel M.

Prog Urol. 2015 Feb;25(2):83-9. doi: 10.1016/j.purol.2014.11.001. Epub 2014 Nov 7. French.

PMID:
25482920
7.

Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.

Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L, Kerbrat P, Chevreau C, Delva R, Rolland F, Theodore C, Roubaud G, Gravis G, Eymard JC, Malhaire JP, Linassier C, Habibian M, Martin AL, Journeau F, Reckova M, Logothetis C, Culine S.

Lancet Oncol. 2014 Dec;15(13):1442-50. doi: 10.1016/S1470-2045(14)70490-5. Epub 2014 Nov 13.

PMID:
25456363
8.

[Management of testicular teratoma: update by the oncology committee of the French association of urology, external genital organs group (CCAFU-OGE)].

Avances C, Camparo P, Durand X, Flechon A, Murez T, Sebe P, Soulie M, Rigaud J; les membres du CCAFU.

Prog Urol. 2014 Dec;24(16):1050-3. doi: 10.1016/j.purol.2014.07.005. Epub 2014 Sep 8. French.

PMID:
25199728
9.

Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocol.

Béranger R, Pérol O, Bujan L, Faure E, Blain J, Le Cornet C, Flechon A, Charbotel B, Philip T, Schüz J, Fervers B.

BMC Cancer. 2014 Aug 4;14:563. doi: 10.1186/1471-2407-14-563.

10.

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.

Selle F, Wittnebel S, Biron P, Gravis G, Roubaud G, Bui BN, Delva R, Bay JO, Fléchon A, Geoffrois L, Caty A, Soares DG, de Revel T, Fizazi K, Gligorov J, Micléa JM, Dubot C, Provent S, Temby I, Gaulet M, Horn E, Brindel I, Lotz JP.

Ann Oncol. 2014 Sep;25(9):1775-82. doi: 10.1093/annonc/mdu198. Epub 2014 Jun 3.

11.

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houédé N, Merino C, Roubaud G, Dallaudiére B, Richaud P, Fléchon A.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6. doi: 10.1038/pcan.2014.17. Epub 2014 May 6. Review.

PMID:
24796290
12.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
13.

[Testicular germ cell tumours and early exposures to pesticides: The TESTEPERA pilot study].

Béranger R, Blain J, Baudinet C, Faure E, Fléchon A, Boyle H, Chasles V, Charbotel B, Schüz J, Fervers B.

Bull Cancer. 2014 Mar;101(3):225-35. doi: 10.1684/bdc.2014.1901. French.

PMID:
24691186
14.

Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.

Fizazi K, Gravis G, Flechon A, Geoffrois L, Chevreau C, Laguerre B, Delva R, Eymard JC, Rolland F, Houede N, Laplanche A, Burcoveanu D, Culine S.

Ann Oncol. 2014 May;25(5):987-91. doi: 10.1093/annonc/mdu099. Epub 2014 Mar 4.

15.

[CCAFU's contribution to the French National Cancer Institute's reference frame: Adrenal malignant tumors].

Sèbe P, Rigaud J, Avancès C, Brunaud L, Caillard C, Camparo P, Carnaille B, Durand X, Fléchon A, Murez T, Mathonnet M, Triponez F, Mirallié E, Coloby P, Soulié M; Les membres de l’AFCE; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S167-74. doi: 10.1016/S1166-7087(13)70054-X. French.

PMID:
24485291
16.

[CCAFU's contribution to the French National Cancer Institute's reference frame: Retroperitoneal sarcomas].

Avancès C, Rigaud J, Camparo P, Durand X, Sèbe P, Fléchon A, Murez T, Coloby P, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S161-6. doi: 10.1016/S1166-7087(13)70053-8. French.

PMID:
24485290
17.

[CCAFU Recommendations 2013: Testicular germ cell cancer].

Durand X, Rigaud J, Avancès C, Camparo P, Fléchon A, Murez T, Sèbe P, Culine S, Iborra F, Mottet N, Coloby P, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S145-60. doi: 10.1016/S1166-7087(13)70052-6. French.

PMID:
24485289
18.

[CCAFU Recommendations 2013: Penile cancer].

Rigaud J, Avancès C, Camparo P, Durand X, Fléchon A, Murez T, Sèbe P, Coloby P, Culine S, Iborra F, Mottet N, Soulié M; Les membres du CCAFU.

Prog Urol. 2013 Nov;23 Suppl 2:S135-44. doi: 10.1016/S1166-7087(13)70051-4. French.

PMID:
24485288
19.

Initial management of testicular cancer: practice survey among urologists and pathologists.

Rigaud J, Durand X, Camparo P, Avances C, Culine S, Sebe P, Flechon A, Murez T, Soulie M; Comittee of Cancerology of Association of French Urology (CCAFU).

Clin Genitourin Cancer. 2014 Aug;12(4):292-9. doi: 10.1016/j.clgc.2013.12.002. Epub 2013 Dec 26.

PMID:
24461624
20.

Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data.

Le Cornet C, Lortet-Tieulent J, Forman D, Béranger R, Flechon A, Fervers B, Schüz J, Bray F.

Eur J Cancer. 2014 Mar;50(4):831-9. doi: 10.1016/j.ejca.2013.11.035. Epub 2013 Dec 23.

PMID:
24369860
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk